AzTrials
AzTrials

Metastatic NRAS MelanomaCHLOROTRAMMELNCT03979651

MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma

A study testing Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2) and Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3) in people with Metastatic NRAS Melanoma, run by Hospices Civils de Lyon at 5 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients with metastatic Neuroblastoma RAS (NRAS) melanoma are currently treated with first line immune checkpoint inhibitors (nivolumab, pembrolizumab). Thus far, no targeted therapy has been approved in NRAS mutated melanoma as a second line treatment, because although the use of a MEK inhibitor (binimetinib) alone… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Metastatic NRAS Melanoma
What is being tested?
Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2) and Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
29 participants
Where
5 sitesFrance
Study dates
15 Oct 2019to 3 Jan 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically confirmed metastatic or locally advanced unresectable malignant melanoma with an activating NRAS mutation.
  • Available archival tissue, or if not, the patient is willing to provide a baseline tumor biopsy
  • Patient must have progressed during or after a first line treatment by immunotherapy (ipilimumab, pembrolizumab, nivolumab).
  • Progression will be confirmed by two consecutive Computed Tomography (CT) assessements separated for at least 4 weeks.
  • Inclusion is possible if patients progress during an adjuvant treatment by immunotherapy or if they progress less than six months after adjuvant treatment discontinuation.
  • If patients progress six months after adjuvant treatment discontinuation, they have to be treated by a second line of immunotherapy before they can be included in the trial.
Show all 23Show fewer
  • Patient age at least 18 years old
  • Patient Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
  • Patient able to provide informed consent and sign approved consent forms to participate in the study and provide tumor samples
  • Patient willing and able to comply with all study procedures and able to take oral medications.
  • Patients must be willing and able to undergo skin or tumor biopsies according to the institute's own guidelines, the study protocol and requirements for such procedures.
  • Patients must have measurable disease as defined by RECIST version 1.1 criteria
  • Adequate bone marrow, renal and liver function determined biologically:
  • Hematologic: Absolute Neutrophil Count (ANC) ≥1.5x10e9 per Liter, platelet count ≥100 x10e9 per Liter, and hemoglobin ≥9grams/deciLiter
  • Hepatic: total bilirubin level ≤1.5 times the Upper Limit of the Normal (ULN) range (except subjects with Gilbert's Syndrome who must have normal direct bilirubin) and Aspartate aminotransferase (ASAT) and Alanine Aminotransferase (ALAT) levels ≤3 ULN. For patients with metastatic disease to the liver allow levels ≤5 ULN
  • Renal: estimated creatinine clearance ≥50ml/min according to the Cockcroft-Gault formula (or local institutional standard method).
  • Albumin ≥ 27 g/l
  • Adequate cardiac function determined by a pre-treatment Electrocardiogram (EKG) and cardiac ultra-sound.
  • Corrected QT (QTc) interval ≤ 450 ms for the male population and ≤ 470ms for the female population
  • Left ventricular ejection fraction (LVEF) ≥50%
  • Women of childbearing potential must have a negative serum or urine pregnancy test at screening.
  • Both male and female patients must agree to the use of 2 methods of contraception, with one method being highly effective and the other being either highly effective or less effective throughout the study and for at least 4 months after last study treatment administration if the risk of conception exists.
  • Women of childbearing potential who are continuously not heterosexually active are exempt from contraceptive requirements. However, women of childbearing who abstain from heterosexual activity on a continuous basis must still undergo pregnancy testing as described in this protocol.

Who cannot join

  • Prior to the first dose of study treatment patient who received systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any investigational therapy within 4 weeks (6 weeks for nitrosurea or mitomycin-C, antibodies like ipilimumab, pembrolizumab and nivolumab) or within 7-half lives of the investigational therapy prior to starting study treatment, whichever is longer.
  • Patient received radiotherapy within 2 weeks prior to the first dose of study treatment except localized radiation therapy for symptomatic bone metastasis
  • Patients with multiple primary malignancies may be enrolled if nonmelanoma tumor(s) are determined stable by treating investigator and do not require active treatment.
  • Patients with symptomatic brain metastases or cranial epidural disease. Asymptomatic patients with brain metastases can be included.
  • Has retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis, or history of Retinal Vein Occlusion (RVO) or any eye condition that would be considered a risk factor for RVO (e.g., uncontrolled glaucoma or ocular hypertension).
  • Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:
Show all 16Show fewer
  • Cardio-vascular disorders: Congestive heart failure New York Heart Association (NYHA) class 3 or 4, unstable angina, uncontrolled cardiac arrhythmias, uncontrolled hypertension. Stroke, myocardial infarction or other ischemic event within 6 months before first dose.
  • History of Glucose-6-Phosphate dehydrogenase (G6PD) deficiency
  • Patients who have neuromuscular disorders that are associated with elevated Creatine Kinase (CK)
  • Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection that under the judgement of the Principal Investigator (PI) may impair absorption of study drugs)
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  • Known positive serology for Human Immunodeficiency Virus (HIV), active Hepatitis B, and/or active Hepatitis C infection.
  • Patients who have undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human chorionic gonadotropin (hCG) laboratory test.
  • Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study
  • Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 Grade≥3)

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

France5 sites

  • CHU Estaing

    Clermont-Ferrand, Clermont Ferrand, 63003

  • CHU Grenoble Alpes

    La Tronche, La Tronche, 38700

  • Centre Hospitalier Lyon Sud

    Lyon, Pierre-Bénite, 69310

  • AP-HP_HOPITAL Saint Louis

    Paris, Paris, 75010

  • INSTITUT Claudius Rigaud

    Toulouse, Toulouse, 31000

Other trials in France

About this study

Official title: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma: A Phase Ib/II Trial of Trametinib Plus Hydroxychloroquine in Patients With NRAS Melanoma

Patients with metastatic Neuroblastoma RAS (NRAS) melanoma are currently treated with first line immune checkpoint inhibitors (nivolumab, pembrolizumab). Thus far, no targeted therapy has been approved in NRAS mutated melanoma as a second line treatment, because although the use of a MEK inhibitor (binimetinib) alone was superior to the gold standard chemotherapy (dacarbazine) in a phase 3 trial, the progression free survival gain was very modest.

In vitro and in vivo work from the study team's lab (McMAHON, Huntsman Cancer Institute (HCI), Salt Lake City), as well as, Ravi Amaravardi and Jean Mulchey-Levy suggests that the activation of autophagy is a mechanism of resistance to BRAF and MEK inhibitors in RAS and RAF mutated cancers, such as melanoma, pediatric brain tumors and pancreatic adenocarcinoma. The study team has shown in vivo, in four different NRAS mutated melanoma Patient Derived Xenograft (PDX) models that the combination of the MEK inhibitor trametinib and the autophagy inhibitor chloroquine results in a more dramatic tumor regression and inhibition than trametinib or chloroquine used as single agents (Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4). In two of the PDX models, the combination resulted in almost complete tumor regression (quasi disappearance) that was not observed in the single agent treatment arms.

Trametinib (MEKINISTR) is an orally available MEK inhibitor that is currently approved in combination with the BRAF inhibitor dabrafenib (TAFINLARR) to treat BRAF mutated metastatic melanoma at the standard dosing of 2 milligrams (mg) once a day. Hydroxychloroquine (PLAQUENILR) is an orally available autophagy inhibitor that has been used for many years to treat autoimmune diseases like lupus, sarcoidosis and rheumatoid arthritis at the standard dosing of 400-600mg/day. For this study, the investigating team would like to evaluate the safety and tolerability of the combination of hydroxychloroquine and trametinib in a phase I trial in patients with NRAS mutated metastatic melanoma.

Being tested
Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)
Keywords
MEK inhibitor, Autophagy inhibition, Metastatic NRAs Melanoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)Drug

    Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.

    The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.

    • Level -1 = Hydroxychloroquine 400 mg by mouth once a day

  • Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)Drug

    Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.

    The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.

    • Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day

  • Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)Drug

    Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.

    The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.

    • Level 2 = Hydroxychloroquine 600 mg by mouth two times a day
Study groups in NCT03979651
Study groupRoleWhat they receive
Patients with NRAS Melanoma (Dose 1)ExperimentalPatients with NRAS Melanoma receiving the 1st dose of the treatment (400 milligrams)
Receives: Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)
Patients with NRAS Melanoma (Dose 2)ExperimentalPatients with NRAS Melanoma receiving the 2nd dose of the treatment (800 milligrams)
Receives: Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)
Patients with NRAS Melanoma (Dose 3)ExperimentalPatients with NRAS Melanoma receiving the 3rd dose of the treatment (600 milligrams twice a day)
Receives: Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    DLTs will be determined weekly during the first cycle of treatment (28 days) in order to choose the optimal dose for the phase II

    Measured: 28 days

  2. Percentage of patients with a partial or complete response to treatment

    Percentage of patients with a partial or complete response to treatment according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines version 1.1 which allows the Evaluation of the Overall Response Rate (ORR) based on 3 main criteria: patients' tumor improves ("responds"), stays the same ("stabilizes"), or worsens ("progresses") during treatment. The comparison of target lesions will be based on a Computed Tomography (CT) scan performed after two cycles of treatment (56 days) to those present on the base line CT prior to treatment initiation.

    Measured: 56 days

Secondary outcomes (11)

  1. Change in Median progression Free survival

    Median progression Free survival will be determined in the cohort treated by the recommended phase 2 dose (RP2D). Subjects who discontinue treatment for reasons other than disease progression will have Computed Tomography (CT) scans at the end of therapy (EOT) visit (unless their previous restaging was performed within 6 weeks).

    Measured: at the end of 2 cycles of treatment (each cycle is 28 days), at the end of the 3rd cycle of treatment and every 12 weeks thereafter up to 12 months

  2. Change in Overall Survival

    Overall Survival will be determined in the cohort treated by the recommended phase 2 dose (RP2D); Subjects who discontinue treatment for reasons other than progression will have Computed Tomography (CT) scans at the end of therapy (EOT) visit (unless their previous restaging was performed within 6 weeks).

    Measured: at the end of 2 cycles of treatment (each cycle is 28 days), at the end of the 3rd cycle of treatment and every 12 weeks thereafter up to 12 months

  3. Safety of the drug combination Trametinib and Hydroxychloroquine

    Adverse events (AEs) and Serious Adverse Events (SAEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be reported

    Measured: 1 year

  4. Quantification of the autophagic substrate p62

    p62 will be quantified by immunohistochemistry (IHC) using a skin punch biopsy of normal tissue in patients without cutaneous metastasis.

    Measured: At Day 1 (before treatment) and Day 15 (after treatment)

  5. Quantification of Microtubule-associated protein Light Chain 3 (LC3)

    LC3 will be quantified by immunohistochemistry (IHC) using a skin punch biopsy of normal tissue in patients without cutaneous metastasis.

    Measured: At Day 1 (before treatment) and Day 15 (after treatment)

  6. Quantification of p-ERK

    p-ERK will be quantified by immunohistochemistry (IHC) using a skin punch biopsy of normal tissue in patients without cutaneous metastasis.

    Measured: At Day 1 (before treatment) and Day 15 (after treatment)

  7. Quantification of the autophagic substrate p62 (cutaneous metastasis)

    p62 will be quantified by immunohistochemistry (IHC) using a skin punch biopsy of normal tissue in patients with cutaneous metastasis.

    Measured: At Day 1 (before treatment) and Day 15 (after treatment)

  8. Quantification of Microtubule-associated protein Light Chain 3 (LC3) (cutaneous metastasis)

    LC3 will be quantified by immunohistochemistry (IHC) using a skin punch biopsy of normal tissue in patients with cutaneous metastasis.

    Measured: At Day 1 (before treatment) and Day 15 (after treatment)

  9. Quantification of p-ERK (cutaneous metastasis)

    p-ERK will be quantified by immunohistochemistry (IHC) using a skin punch biopsy of normal tissue in patients with cutaneous metastasis.

    Measured: At Day 1 (before treatment) and Day 15 (after treatment)

  10. Serum trametinib and hydroxychloroquine concentrations (AUC)

    Serum trametinib and hydroxychloroquine concentrations (AUC) will be evaluated and compared to predicted published concentrations

    Measured: Day 28

  11. Changes in treatment induced immune modifications in patient blood serum

    The evaluation of treatment induced immune modifications in the blood serum will be based on patient peripheral blood mononuclear cell (PBMC) collection

    Measured: At Day 1 (before treatment), at Day 15 (after treatment), at 2 months (after treatment), and at 30 days after last treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2019
  2. Study start15 Oct 2019
  3. Primary completion3 Jan 2023
  4. Study completion3 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
29 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03979651
Sponsor's protocol ID
69HCL19_0115
Other IDs
2019-001399-13, 2019
Acronym
CHLOROTRAMMEL
Status last verified
May 2025
First submitted
5 Jun 2019
Last updated
22 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2) and Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3) in people with Metastatic NRAS Melanoma, run by Hospices Civils de Lyon at 5 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Dose-Limiting Toxicities (DLTs) (time frame: 28 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03979651.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in